- Trials with a EudraCT protocol (71)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
71 result(s) found for: CAR T Cells and ALL.
Displaying page 1 of 4.
EudraCT Number: 2016-004043-36 | Sponsor Protocol Number: 004:TCELL | Start Date*: 2017-04-28 |
Sponsor Name:Uppsala University | ||
Full Title: CD19-TARGETING 3RD GENERATION CAR T CELLS FOR REFRACTORY B CELL MALIGNANCY – A PHASE II TRIAL | ||
Medical condition: CD19+ B cell lymphoma or leukemia | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001393-19 | Sponsor Protocol Number: 003:TCELL | Start Date*: 2014-04-08 |
Sponsor Name:Uppsala university | ||
Full Title: CD19-targeting 3rd generation CAR T cells for refractory B cell malignancy - a phase I/IIa trial. | ||
Medical condition: CD19+ B cell lymphoma or leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001673-14 | Sponsor Protocol Number: CCTL019A2205B | Start Date*: 2015-10-06 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy | ||||||||||||||||||
Medical condition: All patients who have been treated with chimeric antigen receptor (CAR) T-cell therapy in the context of a prior Novartis sponsored or supported study for any indication. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) DE (Trial now transitioned) ES (Ongoing) NO (Ongoing) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) FI (Trial now transitioned) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003409-23 | Sponsor Protocol Number: MERMAID1 | Start Date*: 2023-12-12 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia. Phase I/II clinical trial (MERMAID1) | |||||||||||||
Medical condition: Relapsed and refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004808-60 | Sponsor Protocol Number: HD-CAR-1/V04 | Start Date*: 2018-04-12 | ||||||||||||||||
Sponsor Name:University Hospital Heidelberg | ||||||||||||||||||
Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial | ||||||||||||||||||
Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004310-33 | Sponsor Protocol Number: CAR4SAR | Start Date*: 2022-02-21 |
Sponsor Name:Dr. Antonio Pérez Martínez | ||
Full Title: A Phase I Trial of Memory T Cells Expressing an ANTI-NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults with Advanced Sarcoma | ||
Medical condition: Advanced Sarcoma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004323-20 | Sponsor Protocol Number: BNT211-01 | Start Date*: 2020-06-30 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:BioNTech Cell & Gene Therapies GmbH | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: CLDN6-positive relapsed or refractory advanced solid tumors | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) NL (Ongoing) SE (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002849-30 | Sponsor Protocol Number: CCTL019B2101J/CHP-959 | Start Date*: 2017-11-16 | |||||||||||||||||||||
Sponsor Name:University of Pennsylvania | |||||||||||||||||||||||
Full Title: A Phase I/IIA Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRzeta and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant Or Refractory CD19+ Leuk... | |||||||||||||||||||||||
Medical condition: Chemotherapy resistant or refractory CD19+ B-cell Leukemia and Lymphoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003815-25 | Sponsor Protocol Number: CP0101-CLL | Start Date*: 2022-02-21 |
Sponsor Name:CellPoint B.V. | ||
Full Title: A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (C... | ||
Medical condition: relapsed / refractory Chronic Lymphocytic Leukemia relapsed / refractory Small Lymphocytic Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004324-14 | Sponsor Protocol Number: WU-CART-007-1001 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Wugen, Inc. | ||||||||||||||||||
Full Title: A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic L... | ||||||||||||||||||
Medical condition: Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000186-40 | Sponsor Protocol Number: B1931036 | Start Date*: 2022-10-07 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH RISK FIRST RELAPSE B-CELL... | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) DE (Ongoing) AT (Ongoing) BE (Ongoing) SE (Ongoing) FR (Ongoing) SK (Ongoing) IT (Ongoing) ES (Ongoing) PL (Ongoing) GR (Ongoing) CZ (Ongoing) NL (Ongoing) FI (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001465-24 | Sponsor Protocol Number: GC-LTFU-001 | Start Date*: 2018-02-26 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. | |||||||||||||
Medical condition: Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) AT (Trial now transitioned) FI (Ongoing) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001246-34 | Sponsor Protocol Number: JCAR017-BCM-004 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||
Full Title: A phase 1 / 2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL and B-NHL (TRANSCEND PEDALL) | ||||||||||||||||||||||||||||
Medical condition: Relapsed or refractory (r/r) CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL). | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) DE (Prematurely Ended) ES (Prematurely Ended) IT (Restarted) BE (Completed) NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001985-12 | Sponsor Protocol Number: BiCAR | Start Date*: 2021-02-08 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:LYSARC | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells therapy | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients who received CAR T-cells therapy for R/R DLBCL (cohort 1) or R/R PMBL, mantle cell lymphoma, t-iNHL or iNHL (cohort 2), at least 1 month ago | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001965-26 | Sponsor Protocol Number: AUTO4-TL1 | Start Date*: 2018-02-01 | |||||||||||
Sponsor Name:Autolus Ltd | |||||||||||||
Full Title: A SINGLE ARM, OPEN-LABEL, MULTI-CENTRE, PHASE I/II STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF AUTO4, A CAR T CELL TREATMENT TARGETING TRBC1, IN PATIENTS WITH RELAPSED OR REFRACTORY TRBC1 ... | |||||||||||||
Medical condition: Relapsed or refractory T cell Non-Hodgkin Lymphoma (T-NHL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001937-16 | Sponsor Protocol Number: AUTO1-AL1 | Start Date*: 2020-02-17 | |||||||||||
Sponsor Name:Autolus Limited | |||||||||||||
Full Title: An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating The Safety and Efficacy Of AUTO1, A CAR T Cell Treatment Targeting CD19, In Adult Patients With Relapsed Or Refractory B Cell Acute Lymphob... | |||||||||||||
Medical condition: Relapsed or refractory B cell acute lymphoblastic leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001795-38 | Sponsor Protocol Number: ALLTogether1 | Start Date*: 2020-05-15 | |||||||||||
Sponsor Name:Karolinska University Hospital | |||||||||||||
Full Title: ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL) | |||||||||||||
Medical condition: Acute lymphoblastic leukaemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) FI (Ongoing) SE (Ongoing) DK (Ongoing) IE (Ongoing) GB (GB - no longer in EU/EEA) BE (Ongoing) PT (Ongoing) LT (Ongoing) NO (Ongoing) NL (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000264-28 | Sponsor Protocol Number: bb2121-MM-002 | Start Date*: 2018-10-19 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A Phase 2, Multi-cohort, Open-label, Multi-center Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multi... | ||||||||||||||||||
Medical condition: Relapsed and Refractory Multiple Myeloma and High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Restarted) FR (Ongoing) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003462-40 | Sponsor Protocol Number: 18IC07 | Start Date*: 2020-03-30 |
Sponsor Name:Great Ormond Street Hospital for Children NHS Trust | ||
Full Title: Phase 1 , open label study of CRISPR-CAR genome edited T cells (TT52CAR19) in relapsed /refractory B Cell Acute Lymphoblastic Leukaemia | ||
Medical condition: Relapsed/ refractory B- cell acute lymphoid leukaemia | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002245-29 | Sponsor Protocol Number: BB2121-MM-001 | Start Date*: 2018-10-02 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma | ||||||||||||||||||
Medical condition: Relapsed and Refractory Multiple Myeloma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.